News
On this page find all the latest news, events and activities that involves Dr. Falk Pharma.

First patient treated in phase iib study of Naronapride in patients with gastroparesis
Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…
More

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of…
More

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…
More

Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue…
More

Renexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration Agreement
Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal…
More

TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets
Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza® 0.5mg orally disintegrating budesonide tablet -…
More

Adults with EOE market research survey
Dr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.
More

Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant
Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant has been awarded to
More

Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
SAN DIEGO and FREIBURG, Germany, Aug. 13, 2020 /PRNewswire/ — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to…
More